IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0334775
(2008-12-15)
|
등록번호 |
US-8337830
(2012-12-25)
|
발명자
/ 주소 |
- Franzusoff, Alex
- Bellgrau, Donald
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
8 인용 특허 :
25 |
초록
▼
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use o
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.
대표청구항
▼
1. A method to increase survival, reduce tumor burden, or inhibit tumor growth in a patient that has cancer, comprising the combination of the steps of: a) establishing a stable mixed bone marrow chimerism in a patient that has cancer by nonmyeloablative stem cell transfer, wherein the stem cells ar
1. A method to increase survival, reduce tumor burden, or inhibit tumor growth in a patient that has cancer, comprising the combination of the steps of: a) establishing a stable mixed bone marrow chimerism in a patient that has cancer by nonmyeloablative stem cell transfer, wherein the stem cells are provided by an allogeneic donor;b) administering lymphocytes obtained from the allogeneic donor to the patient; andc) administering to the patient, after step (b) and prior to detection of tumor response in the patient, a composition comprising a yeast vehicle and at least one cancer antigen or immunogenic domain thereof, wherein the cancer antigen or immunogenic domain thereof is expressed by the cancer for which the patient is treated. 2. The method of claim 1, further comprising administering to the allogeneic donor, prior to step (a), a composition comprising a yeast vehicle and at least one cancer antigen or immunogenic domain thereof, wherein the cancer antigen or immunogenic domain thereof is expressed by the cancer for which the patient is treated. 3. The method of claim 1, further comprising removing a tumor from the patient prior to performing step (a). 4. The method of claim 1, wherein the composition comprises at least two or more cancer antigens expressed by the cancer for which the patient is treated. 5. The method of claim 1, wherein the cancer antigen is a fusion protein comprising one or more cancer antigens expressed by the cancer for which the patient is treated. 6. The method of claim 1, wherein the cancer antigen is a fusion protein comprising one or more immunogenic domains of one or more cancer antigens expressed by the cancer for which the patient is treated. 7. The method of claim 1, wherein the cancer antigen consists of a fusion protein construct comprising multiple domains, wherein each domain consists of a peptide from an oncoprotein, the peptide consisting of at least 4 amino acid residues flanking either side of and including a mutated amino acid that is found in the protein, wherein the mutation is associated with tumorigenicity. 8. The method of claim 1, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof. 9. The method of claim 1, wherein the yeast vehicle is a whole yeast. 10. The method of claim 1, wherein the yeast vehicle was loaded intracellularly with the cancer antigen. 11. The method of claim 1, wherein the cancer antigen was covalently or non-covalently attached to the yeast vehicle. 12. The method of claim 1, wherein the yeast vehicle and the cancer antigen were associated by mixing. 13. The method of claim 1, wherein the composition is administered by intranasal administration. 14. The method of claim 1, wherein the composition is administered by parenteral administration. 15. The method of claim 1, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kluveromyces, Hansenula, Candida and Pichia. 16. The method of claim 1, wherein Saccharomyces is S. cerevisiae.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.